Does lowering lipid levels really affect risk for prostate cancer and prostate cancer-specific mortality?

As our regular readers will be well aware, there have been a number of published papers suggesting associations between the use of statins and other lipid-lowering agents and risk for diagnosis with and progression of prostate cancer over time. … READ MORE …

New targeted imaging agents and the diagnosis, prognosis of progressive disease

According to a media release issued today by Progenics Pharmaceuticals, early clinical studies of two of their investigational products — the imaging agents [123I]-MIP-1072 and [123I]-MIP-1095 — suggest potential of these two agents in enhancement of imaging techniques to identify the exact location of cancer in bone, tissue, and the prostate itself. … READ MORE …

Is Trofex a possible “replacement” imaging agent for Combidex?

According to a media release issued on Thursday this week by Molecular Insight Pharmaceuticals, Inc. (MIP), an investigational imaging agent known as Trofex™ (a.k.a, 123I-MIP-1072) may offer a new opportunity to identify the presence of early signs of metastatic prostate cancer in the prostate bed, soft tissues, and bone within 4 hours after injection. … READ MORE …